Deep sinus aspergillosis in a liver transplant recipient successfully treated with a combination of caspofungin and voriconazole (original) (raw)

Abstract

We describe the rare case of a diabetic patient who was successfully treated for cytomegalovirus viremia and leishmaniasis following liver transplantation for hepatitis C virus-related cirrhosis, but also developed invasive sinus Aspergillus infection, while still on liposomal amphotericin B (AmBisome). The patient refused radical surgery including eye enucleation, and received a combination of intravenous caspofungin and voriconazole, along with repeated, conservative, local surgical debridement. At follow-up, 15 months after the onset of sinusitis, the patient remains culture-negative, fully active, and without evidence of local recurrence. Infection with Aspergillus species results in excess mortality rates ranging from 58% to 87% in immunosuppressed patients including organ transplant recipients (1, 2). Traditionally, the standard deoxycholate formulation of amphotericin B has been used in immunocompromised patients with invasive aspergillosis (3) with suboptimal results and signi¢cant toxicity associated with its use. Recently liposomal formulations, when available, have been preferentially used over the traditional formulation in clinical practice. The traditional amphotericin B regimen has been recently shown to be less e¡ective for invasive aspergillosis than therapy with the newer antifungal voriconazole (4). Caspofungin acetate belongs to the newer class of antifungal agents, the echinocandins. Good in vivo and in vitro results against Aspergillus infections have earned its approval for use in refractory invasive Aspergillus infections (5). Combination of antifungals has been reserved for refractory cases only. However, combination therapy may have an important role in treating invasive aspergillosis as a primary option and not as a last resort (6). It is important to note that recently, in vitro synergistic e¡ects have been shown between newer and more traditional antifungal agents (6, 7). Recent trials in invasive fungal infections have shown that combining either caspofungin or voriconazole with amphotericin B has a clear clinical

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (31)

  1. JANTUNEN E, RUUTU P, PIILONEN A,VOLIN L, PARKKALI T, RUUTU T. Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 2000: 26: 759^762.
  2. LIN SJ, SCHRANZ J,TEUTSCH SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001: 32: 358^366.
  3. STEVENS DA, KAN VL, JUDSON MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000: 30: 696^709.
  4. HERBRECHT R, DENNING DW, PATTERSON TF, et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002: 347: 408^415.
  5. HOANG A. Caspofungin acetate: an antifungal agent. Am J Health Syst Pharm 2001: 58: 1206^1214.
  6. LEWIS RE, KONTOYIANNIS DP. Rationale for combination antifungal therapy. Pharmacotherapy 2001: 21: 149S^164S.
  7. KONTOYIANNIS DP, HACHEM R, LEWIS RE, et al. E⁄cacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003: 98: 292^299.
  8. THIEBAUTA SR, ANTAL D, BREYSSE MC, PIVOT C. Refractory invasive fungal infections in patients with hematologic malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B [abstract M-859]. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy.Washington, DC: American Society for Microbiology, 2002: 386.
  9. KIRKPATRICK WR, PEREA S, COCO BJ, PATTERSON TF. E⁄cacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002: 46: 2564^2568.
  10. PETRAITIS V, PETRAITIENE R, SARAFANDI AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Inf Dis 2003: 187: 1834^1843.
  11. PEREA S, GONZALEZ G, FOTHERGILL AW, KIRKPATRICK WR, RINALDI MG, PATTERSON TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002: 46: 3039^3041.
  12. SABO JA, ABDEL-RAHMAN SM.Voriconazole: a new triazole antifungal. Ann Pharmacother 2000: 34: 1032^1043.
  13. MCGINNIS MR, PASARELL L, SUTTON DA, FOTHERGILL AW, COOPER CR, RINALDI MG. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 1997: 41: 1832^1834.
  14. DENNING DW, RIBAUD P, MILPIED N, et al. E⁄cacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002: 34: 563^571.
  15. SUTTON DA, SANCHE SE, REVANKAR SG, FOTHERGILL AW, RINALDI MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Micorbiol 1999: 37: 2343^2345.
  16. DUPONT B, RICHARDSON M,VERWEIJ PE, MEIS JF. Invasive aspergillosis. Med Mycelia 2000: 38 (Suppl. 1): 215^224.
  17. RUBIN MA, CARROLL KC, CAHILL BC. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002: 34: 1160^1161.
  18. MANAVATHU EK, ALANGADEN GJ, CHANDRASEKAR PH. Di¡erential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003: 51: 1423^1425.
  19. IWEN PC, RUPP ME, HINRICHS SH. Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature. Clin Infect Dis 1997: 24: 1178^1184.
  20. WAITZMAN AA, BIRT BD. Fungal sinusitis. J Otolaryngol 1994: 23: 244^249.
  21. KAVANAGH KT, HUGHES WT, PARHAM DM, CHANIN LR. Fungal sinusitis in immunocompromised children with neoplasms. Ann Oto Rhinol Laryn 1991: 100: 331^336.
  22. WILLIAMS P,WASKIN H, BOLCSAK L, SWENSON C. Amphotericin B concentrations in autopsy tissues of organ transplant patients administered amphotericin B lipid complex injection. Transplantation 1999: 67: S93.
  23. WIATRAK BJ,WILLGING P, MYER CM, COTTON RT. Functional endoscopic sinus surgery in the immunocompromised child. Otolaryngol Head Neck Surg 1991: 105: 818^825.
  24. KIMURA M, SMITH MB, MCGINNIS MR. Zygomycosis due to Apophysomyces elegans: report of 2 cases and review of the literature. Arch Pathol Lab Med 1999: 123: 386^390.
  25. DE SHAZO RD, CHAPIN K, SWAIN RE. Fungal sinusitis. N Engl J Med 1997: 337: 254^259.
  26. DENNING DW. Invasive aspergillosis. Clin Infect Dis 1998: 26: 781^805.
  27. DENNING DW, STEVENS DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990: 12: 1147^1201.
  28. HORBER FF, LERUT JP, REICHEN J, ZIMMERMAN A, JAEGER P, MALINVERNI R. Visceral leishmaniasis after orthotopic liver transplantation: impact of persistent splenomegaly. Transplant Int 1993: 6: 55^57.
  29. HERNANDEZ-PEREZ J,YEBRA-BANGO M, JIMENEZ-MARTINEZ E, et al.Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of ¢ve cases and review. Clin Infect Dis 1999: 29: 918^921.
  30. HENNEQUIN C. Prevention of parasitic infections (excluding toxoplasmosis) in immunocompromised patients [in French].
  31. Ann Med Interne (Paris) 1997: 148: 240^245.